Certara's Participation in a Key Healthcare Event
Certara, Inc. (Nasdaq: CERT), recognized as a pioneering force in the field of model-informed drug development, is gearing up for an exciting presentation at the annual J.P. Morgan Healthcare Conference. This highly anticipated event is a prime opportunity for industry leaders to share their latest insights and developments.
Event Details and Presentation Timing
The conference will take place with Certara's management team presenting on January 15th. This specific session is scheduled for 5:15 PM PT, bringing an engaging discourse to attendees on the subject of innovative strategies in drug development.
Transforming Drug Development with Certara
Certara has positioned itself as a leader in accelerating the development of medicines through biosimulation software, groundbreaking technology, and a range of services that revolutionize the traditional approaches to drug discovery. With over 2,400 clients, including biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries, Certara is at the forefront of enhancing drug efficacy and safety.
Engagement with Investors and Clients
The live webcast of Certara’s presentation will be accessible on the investor relations section of their website, ensuring broad access and interaction with interested parties. Following the event, the recorded presentation will be available for at least 30 days, allowing stakeholders to revisit the insights shared during the conference.
The Impact of Biosimulation in Pharmaceuticals
With an increasing emphasis on efficient drug development processes, the role of biosimulation technology is becoming critical. Certara’s innovative offerings facilitate enhanced decision-making throughout the development lifecycle. Their approach not only reduces costs but also improves timelines, ultimately leading to faster access to critical therapies for patients.
Community and Market Reach
Certara's commitment to supporting the global community in pharmaceuticals is apparent in their collaborations and partnerships. By engaging extensively with an array of organizations worldwide, Certara enhances its capabilities and extends its footprint in the industry, demonstrating the tangible impacts of its technologies and methodologies.
Investor Relations and Media Contact
For those interested in further understanding Certara’s innovative initiatives and developments, their Investor Relations contact, David Deuchler of the Gilmartin Group, stands ready to provide further insights. You can reach out via email at ir@certara.com.
Additionally, for any media inquiries, Alyssa Horowitz is available at certara@pancomm.com. Certara's dedication to transparency and communication enhances their relationship with both the investment community and the public.
Frequently Asked Questions
What is Certara's role in drug development?
Certara accelerates drug development through innovative biosimulation software, improving efficacy and safety in the pharmaceutical industry.
When will Certara present at the J.P. Morgan Healthcare Conference?
Certara's management will present on January 15th at 5:15 PM PT.
How can I access the webcast of Certara's presentation?
The live webcast will be available on Certara’s investor relations website.
Who can be contacted for investor relations inquiries at Certara?
David Deuchler from Gilmartin Group is the contact for investor relations inquiries.
What recent advancements has Certara made?
Certara has been enhancing its biosimulation technologies and expanding its global partnerships to facilitate efficient drug development.
